Want to see HK:3860 full AI Analyst Report?
EPS Creative Health Technology Group Limited (3860) AI Stock Analysis
EPS Creative Health Technology Group Limited
(HKEX:3860)
The score is held back primarily by uneven financial performance (return to net losses and volatile revenue), partially offset by improved balance-sheet leverage and a better 2026 cash-flow profile. Technicals add additional pressure with price below key moving averages and negative MACD, while valuation remains challenging due to losses (negative P/E) and only a modest dividend yield.
EPS Creative Health Technology Group Limited (3860) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 337.81M
- Dividend Yield
- 1.72%
- Average Volume (3M)
- 243.33K
- Price to Earnings (P/E)
- -21.9
- Beta (1Y)
- 0.25
- Revenue Growth
- -15.95%
- EPS Growth
- -135.81%
- Country
- Hong Kong
- Employees
- 133
- Sector
- Consumer Cyclical
- Sector Strength
- 61
- Industry
- Apparel - Retail
EPS Creative Health Technology Group Limited Business Overview & Revenue Model
Company Description
EPS Creative Health Technology Group Limited functions as an investment holding company with diverse operations. It specializes in comprehensive apparel supply chain management, serving clients across Hong Kong, mainland China, Japan, the United Stat...
How the Company Makes Money
null
EPS Creative Health Technology Group Limited Financial Statement Overview
Summary
Overall fundamentals are mixed. The balance sheet is a clear strength with materially reduced leverage and solid equity support (Balance Sheet Score 70). However, operating performance is unstable—revenue and profitability have been volatile with a return to a net loss in 2026 (Income Statement Score 42). Cash flow turned positive with solid free cash flow in 2026 (Cash Flow Score 55), but consistency and alignment with earnings remain concerns.
Income Statement
42NeutralBalance Sheet
70PositiveCash Flow
55Neutral| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 457.65M | 457.65M | 544.52M | 644.62M | 452.91M | 519.95M |
| Gross Profit | 75.02M | 75.02M | 94.58M | 99.26M | 67.85M | 76.78M |
| EBITDA | 17.63M | 17.63M | 57.53M | -2.96M | -37.88M | -14.53M |
| Net Income | -13.85M | -13.85M | 38.59M | -22.07M | -45.74M | -22.60M |
Balance Sheet | ||||||
| Total Assets | 311.39M | 311.39M | 336.85M | 429.88M | 227.49M | 248.92M |
| Cash, Cash Equivalents and Short-Term Investments | 130.49M | 130.49M | 135.69M | 131.51M | 131.47M | 208.14M |
| Total Debt | 4.45M | 4.45M | 57.22M | 11.45M | 73.61M | 9.14M |
| Total Liabilities | 158.67M | 158.67M | 174.33M | 291.70M | 135.85M | 122.22M |
| Stockholders Equity | 105.91M | 105.91M | 120.68M | 65.36M | 87.64M | 131.32M |
Cash Flow | ||||||
| Free Cash Flow | 25.11M | 25.11M | -23.63M | -33.60M | -40.52M | 9.99M |
| Operating Cash Flow | 28.21M | 28.21M | -17.92M | -28.57M | -38.11M | 10.05M |
| Investing Cash Flow | -3.09M | -2.98M | 57.20M | -20.40M | -11.38M | 4.57M |
| Financing Cash Flow | -32.76M | -37.51M | -16.78M | 33.66M | -27.75M | 98.11M |
EPS Creative Health Technology Group Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3860, the sentiment is Negative. The current price of 0.58 is below the 20-day moving average (MA) of 0.59, below the 50-day MA of 0.59, and below the 200-day MA of 0.60, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 44.70 is Neutral, neither overbought nor oversold. The STOCH value of 68.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3860.
EPS Creative Health Technology Group Limited Peers Comparison
Overall Rating
HK:070972.4Outperform
HK:628871Outperform
HK:136868Neutral
HK:611066Neutral
HK:370964.6Neutral- HK:386051Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0709 | 72Outperform | HKD 2.01B | 9.87 | 10.15% | 10.52% | -2.94% | -6.03% |
| HK:6288 | 71Outperform | HKD 1.18T | 42.61 | 20.26% | 0.79% | 11.14% | 19.43% |
| HK:1368 | 68Neutral | HKD 9.51B | 6.35 | 12.21% | 7.80% | 10.47% | -8.83% |
| HK:6110 | 66Neutral | HKD 6.85B | 5.35 | 13.22% | 22.96% | -3.43% | -0.67% |
| HK:3709 | 65Neutral | HKD 2.81B | 5.99 | 8.44% | 8.55% | -4.39% | -12.10% |
| Sector * | 61Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
| HK:3860 | 51Neutral | HKD 337.81M | -21.89 | -12.65% | 1.72% | -15.95% | -135.81% |
* Consumer Cyclical Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:3860 | EPS Creative Health Technology Group Limited | 0.58 | -0.13 | -18.31% | |
| HK:0709 | Giordano International | 1.25 | -0.11 | -8.32% | |
| HK:1368 | Xtep International Holdings | 3.52 | -1.70 | -32.51% | |
| HK:3709 | EEKA Fashion Holdings Limited | 4.09 | -3.49 | -45.98% | |
| HK:6110 | Topsports International Holdings Limited | 1.10 | -1.46 | -56.92% | |
| HK:6288 | Fast Retailing Co Ltd Shs Unsponsored Hong Kong Depositary Receipt Repr 1/100th Sh | 36.84 | 8.84 | 31.57% |
EPS Creative Health Technology Group Limited Corporate Events
EPS Creative Health Technology Faces Governance Gap After Independent Director Resigns
EPS Creative Health Technology Group Limited announced the resignation of independent non-executive director Mr. Choi Koon Ming, effective 9 October 2026, as he seeks to focus on other business commitments. His departure also ends his roles as chairm...
EPS Creative Health Technology Updates Board and Committee Structure
EPS Creative Health Technology Group Limited has detailed the composition of its board of directors, naming six executive directors, one non-executive director and three independent non-executive directors. The leadership team spans core functions su...
EPS Creative Health Issues Profit Warning on Rising Losses and Margin Pressure
EPS Creative Health Technology Group Limited has warned that it expects a higher loss after tax of about HK$8 million to HK$12 million for the six months ended 30 September 2026, compared with the same period a year earlier. The board attributes this...
EPS Creative Health Tech’s Controlling Shareholder to Sell 22% Stake While Retaining Control
EPS Creative Health Technology Group Limited has announced that controlling shareholder EPS Holdings, Inc. has agreed to sell up to 130 million shares, or 22.32% of the company’s issued share capital, to Hong Kong‑based Wisdoms Group Inte...
EPS Creative Health Technology Wins Shareholder Approval for 2026 Framework Purchase Deal
Independent shareholders of EPS Creative Health Technology Group Limited have approved the 2026 Framework Purchase Agreement and its annual caps for the three financial years ending 31 March 2029. The resolution passed unanimously by poll at an extra...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 29, 2026